Although no clinical predictors of ICH were confirmed, we noted a possible trend in patients treated with the anti-VEGF agent bevacizumab.
← all excerpts
Intracranial hemorrhage in patients with primary brain cancer receiving anticoagulation.
2
—
—
The sentences
Although the difference in ICH rates between DOAC- and LMWH-treated patients did not reach statistical significance, the absence of severe bleeding among DOAC users is clinically relevant.